- Announced positive topline data from Phase 2 trial in chronic spontaneous urticaria; results showed ozureprubart at both Q8W and Q12W dosing had comparable efficacy and safety to omalizumab at Q4W ...
Topline 36-week data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II studies on track for readouts by year-end 2025 Oral small molecule amylin receptor agonist ...
Presented new preclinical data on INB-619, a novel gamma-delta (γδ) T cell engager (TCE), demonstrating equivalent potency comparable to FDA-approved commercial products with minimal adverse cytokine ...
MORRISTOWN, N.J., Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver ...
View original content to download multimedia:https://www.prnewswire.com/news-releases/whitehawk-therapeutics-reports-third-quarter-2025-financial-results-and-recent ...
– Continuing to advance Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy; on track to provide program update in Q4 2025 – – Initiated Phase 1 healthy adult trial of EDG-15400 for ...
SafeAir Certified Mold Inspection Inc., a trusted name in indoor air quality and mold testing services across Georgia, has released an in-depth blog post titled “Top Benefits of Hiring a Certified ...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) therapies, today reported its financial results for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback